Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies

Mostrar otras versiones (1)

BACKGROUND: We have reported that seroconversion rates after the second dose of mRNA‐based COVID‐19 vaccines for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were 100% and 95% respectively, with no significant difference from healthy controls (HCs).However, there are very limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Akio, Onozawa, Masahiro, Kobayashi, Mirei, Tsukamoto, Shihori, Senjo, Hajime, Ishio, Takashi, Yokoyama, Emi, Kanaya, Minoru, Izumiyama, Koh, Saito, Makoto, Muraki, Haruna, Morioka, Masanobu, Teshima, Takanori, Kondo, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501249/
https://www.ncbi.nlm.nih.gov/pubmed/37409608
http://dx.doi.org/10.1002/cam4.6314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501249/
https://www.ncbi.nlm.nih.gov/pubmed/37409608
http://dx.doi.org/10.1002/cam4.6314

Ejemplares similares